The Cooper Companies, Inc. (COO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $76.73. The rating moved from Overbought to Neutral on August 17, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$76.73
• Last changeMoved from Overbought to Neutral on August 17, 2026
• SectorHealthcare
• IndustryMedical Instruments & Supplies

AI analysis

The Cooper Companies, Inc. (COO) combines a durable contact-lens consumables franchise with a growing ophthalmic surgical business, producing steady cash flow and attractive margins. Near-term performance is tied to consumer replacement patterns and elective procedure volumes; product innovation and modest M&A could re-accelerate top-line growth. Current market conditions are neutral, with no major macro or geopolitical catalysts in the last several hours. Key risks include demand softness in lenses, competitive pricing pressure, regulatory uncertainty, and FX/supply disruptions. On balance, the company appears fundamentally stable with a mixed near-term outlook and clearer upside tied to surgical adoption and any successful new product launches.

Key factors

• Established market position in contact lenses and ophthalmic surgery supplies with recognizable brand and broad distribution
• Historically strong free cash flow generation and solid gross margins supporting reinvestment and shareholder returns
• Exposure to elective procedure volumes (surgical ophthalmology) provides medium-term growth runway if procedure demand recovers
• Diverse revenue mix (vision care consumables + specialty surgical products) provides some resilience versus single-product businesses
• Potential catalysts: incremental uptake in surgical products, product launches, and selective M&A to extend growth

Risks

• Softness in contact-lens replacement cycles and consumer demand that depresses near-term revenue growth
• Intense competition from larger ophthalmic players and private-label entrants pressuring pricing and share
• Regulatory or reimbursement headwinds affecting surgical device adoption or product approvals
• FX and supply-chain disruptions that could compress margins or delay shipments
• Limited visibility into short-term order flow given quiet macro headlines and sector rotation dynamics

Latest MarketMoodz coverage

• Lululemon and Micron Lead Premarket Movers on Earnings, Guidance2026-06-05

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.